A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC

References

• Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–11. doi:10.1053/j.gastro.2017.08.023.
   PubMed Web of Science ®Google Scholar
• Hsieh CH, Kuan WH, Chang WL, Kuo I-Y, Liu H, Shieh D-B, Liu H, Tan B, Wang Y-C. Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma. J Biomed Sci. 2022;29:90. doi:10.1186/s12929-022-00873-4.
   PubMed Web of Science ®Google Scholar
• Dong P, Xiong Y, Yue J, Hanley S, Watari H. B7H3 as a promoter of metastasis and promising therapeutic target. Front Oncol. 2018;8:264. doi:10.3389/fonc.2018.00264.
   PubMed Web of Science ®Google Scholar
• Wang J, Chong KK, Nakamura Y, Nguyen L, Huang SK, Kuo C, Zhang W, Yu H, Morton DL, Hoon DSB, et al. B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol. 2013;133(8):2050–2058. doi:10.1038/jid.2013.114.
   PubMed Web of Science ®Google Scholar
• Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, Ferrone S. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. 2021;27:1227–1235. doi:10.1158/1078-0432.CCR-20-2584.
   PubMed Web of Science ®Google Scholar
• Zhou WT, Jin WL. B7-H3/CD276: An Emerging Cancer Immunotherapy. Front Immunol. 2021;12:701006. doi:10.3389/fimmu.2021.701006.
   PubMed Web of Science ®Google Scholar
• Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, Zang X. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev. 2017;276(1):26–39. doi:10.1111/imr.12521.
   PubMed Web of Science ®Google Scholar
• Leitner J, Klauser C, Pickl WF, Stöckl J, Majdic O, Bardet AF, Kreil DP, Dong C, Yamazaki T, Zlabinger G, et al. B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction. Eur J Immunol. 2009;39(7):1754–1764. doi:10.1002/eji.200839028.
   PubMed Web of Science ®Google Scholar
• Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22(14):3425–3431. doi:10.1158/1078-0432.CCR-15-2428.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen J, Xu B, Wang, Qi, Zhou W, Zhang G, Sun J, Shi L, Pei H, Wu C, Jiang J, et al. B7-H3 expression associates with tumor invasion and patient’s poor survival in human esophageal cancer. Am J Transl Res. 2015;7:2646–60.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo H-F, Larson SM, Cheung NKV. Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. J Biol Chem. 2015;290:30018–30029. doi:10.1074/jbc.M115.679852.
   PubMed Web of Science ®Google Scholar
• Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Bonvini E, Koenig S, et al. Fc Optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res. 2007;67:8882–8890. doi:10.1158/0008-5472.CAN-07-0696.
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA. 2006;103(11):4005–4010. doi:10.1073/pnas.0508123103.
   PubMed Web of Science ®Google Scholar
• Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589. doi:10.1038/s41586-021-03819-2.
   PubMed Web of Science ®Google Scholar
• Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, et al. AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022;50(D1):D439–D444. doi:10.1093/nar/gkab1061.
   PubMed Web of Science ®Google Scholar
• Sivasubramanian A, Sircar A, Chaudhury S, Gray JJ. Toward high-resolution homology modeling of antibody fv regions and application to antibody-antigen docking. Proteins. 2009;74:497–514. doi:10.1002/prot.22309.
   PubMed Web of Science ®Google Scholar
• Marze NA, Lyskov S, Gray JJ. Improved prediction of antibody VL-VH orientation. Protein Eng Des Sel. 2016;29:409–418. doi:10.1093/protein/gzw013.
   PubMed Web of Science ®Google Scholar
• Weitzner BD, Gray JJ. Accurate structure prediction of CDR H3 loops enabled by a novel structure-based C-Terminal constraint. J Immunol. 2017;198(1):505–515. doi:10.4049/jimmunol.1601137.
   PubMed Web of Science ®Google Scholar
• Weitzner BD, Jeliazkov JR, Lyskov S, Marze N, Kuroda D, Frick R, Adolf-Bryfogle J, Biswas N, Dunbrack RL, Gray JJ, et al. Modeling and docking of antibody structures with Rosetta. Nat Protoc. 2017;12(2):401–416. doi:10.1038/nprot.2016.180.
   PubMed Web of Science ®Google Scholar
• Lyskov S, Chou FC, Conchuir SO, Der BS, Drew K, Kuroda D, Xu J, Weitzner BD, Renfrew PD, Sripakdeevong P, et al. Serverification of molecular modeling applications: the Rosetta online server that includes everyone (ROSIE). PloS One. 2013;8:e63906. doi:10.1371/journal.pone.0063906.
   PubMed Web of Science ®Google Scholar
• Pierce BG, Hourai Y, Weng Z, Keskin O. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PloS One. 2011;6(9):e24657. doi:10.1371/journal.pone.0024657.
   PubMed Web of Science ®Google Scholar
• Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, Klauser C, Zlabinger G, Pickl WF, Stöckl J, Knapp W, et al. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four ig-like domains. J Immunol. 2004;172(4):2352–2359. doi:10.4049/jimmunol.172.4.2352.
   PubMed Web of Science ®Google Scholar
• Zhou YH, Chen YJ, Ma ZY, Xu L, Wang Q, Zhang G-B, Xie F, Ge Y, Wang X-F, Zhang X-G, et al. 4IgB7-H3 is the major isoform expressed on immunocytes as well as malignant cells. Tissue Antigens. 2007;70(2):96–104. doi:10.1111/j.1399-0039.2007.00853.x.
   PubMedGoogle Scholar
• Sun J, Fu F, Gu W, Yan R, Zhang G, Shen Z, Zhou Y, Wang H, Shen B, Zhang X, et al. Origination of new immunological functions in the costimulatory molecule B7-H3: the role of exon duplication in evolution of the immune system. PloS One. 2011;6(9):e24751. doi:10.1371/journal.pone.0024751.
   PubMed Web of Science ®Google Scholar
• Yuan H, Wei X, Zhang G, Li C, Zhang X, Hou J. B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol. 2011;186(3):1093–1099. doi:10.1016/j.juro.2011.04.103.
   PubMed Web of Science ®Google Scholar
• Zhao X, Li DC, Zhu XG, GAN W-J, LI Z, XIONG F, ZHANG Z-X, ZHANG G-B, ZHANG X-G, ZHAO H, et al. B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med. 2013;31(2):283–291. doi:10.3892/ijmm.2012.1212.
   PubMed Web of Science ®Google Scholar
• Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104:19458–19463. doi:10.1073/pnas.0709802104.
   PubMed Web of Science ®Google Scholar
• Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O. B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer. 2012;131:2528–2536. doi:10.1002/ijc.27566.
   PubMed Web of Science ®Google Scholar
• Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 2010;23(8):1104–1112. doi:10.1038/modpathol.2010.95.
   PubMed Web of Science ®Google Scholar
• Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014;40(1):121–127. doi:10.1016/j.ejso.2013.08.023.
   PubMed Web of Science ®Google Scholar
• Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, Donzelli M, Wolden SL, Haque S, Dunkel I, et al. Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies. J Hematol Oncol. 2022;15:165. doi:10.1186/s13045-022-01383-4.
   PubMed Web of Science ®Google Scholar
• Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C. Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep. 2018;45(6):2935–2940. doi:10.1007/s11033-018-4427-x.
   PubMed Web of Science ®Google Scholar
• Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer. 2013;1:12. doi:10.1186/2051-1426-1-12.
   PubMedGoogle Scholar
• Mossner E, Brunker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402. doi:10.1182/blood-2009-06-225979.
   PubMed Web of Science ®Google Scholar
• Schlam I, Nunes R, Lynce F. Profile of Margetuximab: evidence to date in the targeted treatment of metastatic HER2-positive breast cancer. Onco Targets Ther. 2022;15:471–478. doi:10.2147/OTT.S272197.
   PubMed Web of Science ®Google Scholar
• Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, et al. Development of an Fc-enhanced anti–B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012;18:3834–3845. doi:10.1158/1078-0432.CCR-12-0715.
   PubMed Web of Science ®Google Scholar
• Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody. Blood. 2010;115:1204–1213. doi:10.1182/blood-2009-06-229039.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang L, Qian J, Lin J, Chen Q, Yuan Q, Zhou J, Zhang T, Shi J, Zhou H, et al. Expression characteristic of 4Ig B7-H3 and 2Ig B7-H3 in acute myeloid leukemia. Bioengineered. 2021;12(2):11987–12002. doi:10.1080/21655979.2021.2001182.
   PubMed Web of Science ®Google Scholar
• Nagase-Zembutsu A, Hirotani K, Yamato M, Yamaguchi J, Takata T, Yoshida M, Fukuchi K, Yazawa M, Takahashi S, Agatsuma T, et al. Development of DS-5573a: a novel afucosylated mAb directed at B7-H3 with potent antitumor activity. Cancer Sci. 2016;107(5):674–681. doi:10.1111/cas.12915.
   PubMed Web of Science ®Google Scholar
• Cleary K, Chan H, James S, Glennie MJ, Cragg MS. Antibody distance from the cell membrane regulates antibody effector mechanisms. J Immunol. 2017;198(10):3999–4011. doi:10.4049/jimmunol.1601473.
   PubMed Web of Science ®Google Scholar
• Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, Morris K, Szot C, Morris H, Swing DA, et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell. 2017;31:501–515. doi:10.1016/j.ccell.2017.03.005.
   PubMed Web of Science ®Google Scholar